Cell-Free Fetal DNA Testing Market Regional Analysis, Revenue And Growth Rate Report By 2025
“The primary factor for the growth of global cell-free fetal DNA testing industry is growing awareness in the people and requirement of safe or low risk obstetric procedures for prenatal testing. The technology which is used in cell-free DNA analysis and its application to prenatal screening for aneuploidy is rapidly changing.”
The cell-free fetal DNA (cffDNA) test is a new technology being used to assess the risk of a pregnant woman’s developing baby (fetus) against any abnormalities such as chromosome disorder like Down sydrome (trisomy 21), Edwards syndrome (trisomy 18) or Patau syndrome (trisomy 13). The global cell-free fetal DNA testing market is segmented on the basis of test types and geography. This new technology is being used as an alternative to currently available prenatal tests. It may be used to identify other rare conditions resulting from an extra chromosome or missing piece of chromosome (microdeletion). This new prenatal disorder testing technology is expected to be driven by major factors such as safe and low risk obstetric nature of this technology for prenatal testing coupled with increasing awareness about inherited disorders. The two predominant prenatal tests are chorionic villus sampling (CVS) and amniocentesis, both are invasive and could possess harm to the developing fetus, in some cases it can cause miscarriage. Cell-free fetal DNA is a new alternative of prenatal tests. Fetal DNA is found in mother’s blood stream, cell-free fetal DNA enters into the blood stream through the placenta, placenta is a flattened organ in the uterus where maternal blood and fetal blood. The fetal DNA can be split into very acute fragments, less than 200 base pairs on an average. Maternal DNA fragments are also present in the blood. Browse Full Research Report @ https://www.millioninsights.com/industry-reports/cell-free-fetal-dna-cffdna-testing-market